GB2602123B - Composition for procedural sedation and use thereof - Google Patents

Composition for procedural sedation and use thereof Download PDF

Info

Publication number
GB2602123B
GB2602123B GB2020153.9A GB202020153A GB2602123B GB 2602123 B GB2602123 B GB 2602123B GB 202020153 A GB202020153 A GB 202020153A GB 2602123 B GB2602123 B GB 2602123B
Authority
GB
United Kingdom
Prior art keywords
composition
procedural sedation
sedation
procedural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2020153.9A
Other versions
GB2602123A (en
GB202020153D0 (en
Inventor
Julian De Silva Don
Du Plessis Andre
Botha Willem
Von Backstrom Andre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre London Ltd
Original Assignee
Centre London Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre London Ltd filed Critical Centre London Ltd
Priority to GB2020153.9A priority Critical patent/GB2602123B/en
Publication of GB202020153D0 publication Critical patent/GB202020153D0/en
Publication of GB2602123A publication Critical patent/GB2602123A/en
Application granted granted Critical
Publication of GB2602123B publication Critical patent/GB2602123B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
GB2020153.9A 2020-12-18 2020-12-18 Composition for procedural sedation and use thereof Active GB2602123B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB2020153.9A GB2602123B (en) 2020-12-18 2020-12-18 Composition for procedural sedation and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2020153.9A GB2602123B (en) 2020-12-18 2020-12-18 Composition for procedural sedation and use thereof

Publications (3)

Publication Number Publication Date
GB202020153D0 GB202020153D0 (en) 2021-02-03
GB2602123A GB2602123A (en) 2022-06-22
GB2602123B true GB2602123B (en) 2023-08-16

Family

ID=74221197

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2020153.9A Active GB2602123B (en) 2020-12-18 2020-12-18 Composition for procedural sedation and use thereof

Country Status (1)

Country Link
GB (1) GB2602123B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016102463A1 (en) * 2014-12-23 2016-06-30 Bosteels Arnaud Combination of remifentanil and propofol

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016102463A1 (en) * 2014-12-23 2016-06-30 Bosteels Arnaud Combination of remifentanil and propofol

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Anesthesiology Abstract of Scientific Papers Annual Meeting 2003, Abstract No. A-1104, 2003, Wappler et al. "Does intraarticular administration of ketamine reduce postoperative pain in patients undergoing arthroscopic knee surgery?" *
Archives of Iranian Medicine, vol. 19, No. 4, 2016, Ayazoglu et al. "Management of anesthesia during lung transplantations in a single Turkish center", pages 262-268 *
BMJ, vol. 357, 2017, Magill, "Dexamethasone versus standard treatment for postoperative nausea and vomiting in gastrointestinal surgery: randomised controlled trial (DREAMS Trial)", pages 1-10 *
European Journal of Hospital Pharmacy, vol. 24, No. 5, 2016, Gersonde et al. "Physicochemical compatibility and emulsion stability of propofol with commonly used analgesics and sedatives in an intensive care unit", pages 293-303 *
Indian Journal of Anaesthesia, vol. 64, No. 7, 2020, Salgaonkar et al. "Total intravenous anaesthesia with tumescent infiltration anaesthesia with definitive airway for early excision and skin grafting in a major burn - A prospective observational study", pages 611-617 *
International Journal of Clinical Pharmacology and Therapeutics, vol. 48, No. 8, 2010, Hadi et al. "Remifentanil in combination with ketamine versus remifentanil in spinal fusion surgery - A double blind study", page 542-548 *
Journal of Clinical Anesthesia, vol. 27, 2015, Tuncali et al. "Addition of low-dose ketamine to midazolam-fentanyl-propofol-based sedation for colonoscopy: a randomized, double-blind, controlled trial", pages 301-306 *
Journal of Pediatric Gastroenterology and Nutrition, vol. 51, No. 5, 2010, Hirsh et al. "Remifentanil versus fentanyl for esophagogastroduodenoscopy in children", pages 618-621 *
Lab Animal, vol. 39, No. 10, 2010, Demestiha et al. "Refined induction of anesthesia with remifentanil after bolus propofol administration in Landrace/Large White swine", pages 319-324 *

Also Published As

Publication number Publication date
GB2602123A (en) 2022-06-22
GB202020153D0 (en) 2021-02-03

Similar Documents

Publication Publication Date Title
GB202106282D0 (en) Composition and use thereof
EP4063489A4 (en) Composition and use thereof
EP4138879A4 (en) Methods and compositions
EP4084784A4 (en) Compositions and methods
EP4134068A4 (en) Bendamustine composition and use thereof
GB202004677D0 (en) Methods and compositions
GB2602123B (en) Composition for procedural sedation and use thereof
EP4181941A4 (en) Compositions and uses thereof
FI4103161T3 (en) Compositions and uses thereof
GB202014160D0 (en) Senolytic compounds and compositions
GB202102228D0 (en) Composition and use thereof
GB202014427D0 (en) Composition and use
GB202107254D0 (en) Compositions and use thereof
GB202016697D0 (en) Compound and composition for use
GB202106861D0 (en) Composition and uses
GB202114798D0 (en) New uses and compositions
GB202016094D0 (en) New compositions and uses thereof
GB202111289D0 (en) Compositions and uses thereof
GB202110657D0 (en) Compositions and uses thereof
GB202107615D0 (en) Compositions and uses thereof
GB202107614D0 (en) Compositions and uses thereof
GB202107399D0 (en) Compositions and uses thereof
GB202105108D0 (en) Compositions and uses thereof
GB202018414D0 (en) Compositions and uses thereof
GB202016492D0 (en) Compositions and uses thereof